Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$111.92B | 25.7x | 0.3 | HK$18.54 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.7% Upside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$63.82B | 6.8x | -2.19 | HK$20.55 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15% Upside | Upgrade to Pro+ | |
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$62.40B | -44.4x | -4.21 | HK$37.80 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.1% Upside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$59.53B | 13.8x | 0.2 | HK$3.28 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 31.4% Upside | Upgrade to Pro+ | |
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$57.90B | 10.7x | -0.7 | HK$5 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.2% Upside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$48.90B | 11.4x | -1.54 | HK$13.20 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.9% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$37.88B | 17x | -0.73 | HK$14.22 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.8% Upside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$33.74B | 8.4x | 0.79 | HK$5.40 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.5% Upside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$33.01B | 48.1x | 0.44 | HK$28.75 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.6% Upside | Upgrade to Pro+ | |
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$32.29B | 39.3x | -0.52 | HK$54.90 | 7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 45.9% Upside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$29.59B | 8x | -0.65 | HK$18.14 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.1% Upside | Upgrade to Pro+ | |
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$24.51B | 17.3x | 8.3 | HK$26.95 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$22.83B | -70.1x | 7.87 | HK$26.65 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 49.5% Upside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$21.45B | -9.7x | -0.95 | HK$21.80 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$20.28B | 6.6x | 0.2 | HK$11.26 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.1% Upside | Upgrade to Pro+ | |
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$18.92B | 12.9x | -0.22 | HK$7.86 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.5% Upside | Upgrade to Pro+ | |
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$18.49B | -117.6x | 0.6 | HK$4.09 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.2% Downside | Upgrade to Pro+ | |
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$18.16B | -14.4x | 0.11 | HK$7.08 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.5% Upside | Upgrade to Pro+ | |
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$16.53B | 6.8x | 3.34 | HK$4.73 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.7% Upside | Upgrade to Pro+ | |
3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$14.51B | 8.4x | -0.71 | HK$6.19 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.7% Upside | Upgrade to Pro+ | |
Shanghai Junshi Biosciences | Hong Kong | Healthcare | Pharmaceuticals | HK$13.12B | -6.8x | -0.77 | HK$13.36 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.3% Upside | Upgrade to Pro+ | |
Cansino Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$12.45B | -8.9x | -0.31 | HK$33.15 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.3% Downside | Upgrade to Pro+ | |
China Traditional Chinese Medicine | Hong Kong | Healthcare | Pharmaceuticals | HK$11.78B | 12.1x | -8.6 | HK$2.34 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.9% Upside | Upgrade to Pro+ | |
Henlius Biotech | Hong Kong | Healthcare | Pharmaceuticals | HK$11.69B | 16.3x | 0.04 | HK$22.15 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.2% Downside | Upgrade to Pro+ | |
SSY Group | Hong Kong | Healthcare | Pharmaceuticals | HK$10.38B | 7.7x | 0.51 | HK$3.52 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Luye Pharma Group | Hong Kong | Healthcare | Pharmaceuticals | HK$9.22B | 11.1x | 0.19 | HK$2.45 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Yichang Hec Changjiang Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$8.26B | 4.7x | 0.1 | HK$9.39 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.8% Upside | Upgrade to Pro+ | |
AIM Vaccine | Hong Kong | Healthcare | Pharmaceuticals | HK$8.24B | -4x | 0.06 | HK$6.83 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Shineway Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$7.39B | 6.2x | 0.25 | HK$9.78 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.6% Upside | Upgrade to Pro+ | |
Beijing Tong Ren Tang | Hong Kong | Healthcare | Pharmaceuticals | HK$6.91B | 14x | -0.48 | HK$8.28 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47% Upside | Upgrade to Pro+ |